 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456789101112 |
- alendronate / Generic mfg.
Trial termination: Pilot Study of Fosamax in Spinal Cord Injury (clinicaltrials.gov) - Sep 11, 2013
P=N/A, N=1, Terminated, Sponsor: University of Rochester
Recruiting --> Terminated; Only 1 participant enrolled since the beginning of this study
- alendronate / Generic mfg.
Enrollment change: Pilot Study of Fosamax in Spinal Cord Injury (clinicaltrials.gov) - Sep 11, 2013
P=N/A, N=1, Terminated, Sponsor: University of Rochester
Recruiting --> Terminated; Only 1 participant enrolled since the beginning of this study N=10 --> 1
- alendronate / Generic mfg.
Enrollment open: BOCOMEDEN: Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=280, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=10 --> 1 Not yet recruiting --> Recruiting
- |||||| Evenity (romosozumab) / Astellas, Amgen, UCB
Enrollment open: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jul 7, 2013
P3, N=4000, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Ongoing --> Recruiting
- | risedronate / Generic mfg., alendronate / Generic mfg.
New P4 trial: Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy (clinicaltrials.gov) - Jun 18, 2013
P4, N=11, Completed, Sponsor: Gilles Boire
- | alendronate / Generic mfg.
Trial completion: Osteoporosis Prevention With Low Dose Alendronate (clinicaltrials.gov) - May 27, 2013
P3, N=83, Completed, Sponsor: University Hospital of Mont-Godinne
Ongoing --> Recruiting Enrolling by invitation --> Completed
- || alendronate / Generic mfg.
New P3 trial: OSCYF: Treatment of Low Bone Density in Cystic Fibrosis. (clinicaltrials.gov) - Mar 14, 2013
P3, N=171, Completed, Sponsor: Istituto Auxologico Italiano
- |||||| Tymlos (abaloparatide) / Radius, Teijin
Enrollment open: ACTIVExtend: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis (clinicaltrials.gov) - Mar 10, 2013
P3, N=1200, Recruiting, Sponsor: Radius Health, Inc.
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- ||||||| anastrozole / Generic mfg., alendronate / Generic mfg.
Trial completion: BATMAN: Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment (clinicaltrials.gov) - Mar 10, 2013
P3, N=303, Completed, Sponsor: Barwon Health
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| zoledronic acid / Generic mfg., alendronate / Generic mfg.
Enrollment closed: Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation (clinicaltrials.gov) - Feb 10, 2013
P2/3, N=84, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Completed --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: RA Denosumab on Bone Microstructure Study (clinicaltrials.gov) - Jan 15, 2013
P4, N=40, Not yet recruiting, Sponsor: Chinese University of Hong Kong
- raloxifene hydrochloride / Generic mfg., alendronate / Generic mfg.
Trial completion, Monotherapy: Confors: Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis (clinicaltrials.gov) - Dec 29, 2012
P4, N=125, Completed, Sponsor: Medical University of Vienna
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (clinicaltrials.gov) - Dec 13, 2012
P4, N=40, Recruiting, Sponsor: Massachusetts General Hospital
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy (clinicaltrials.gov) - Oct 28, 2012
P3, N=870, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Tymlos (abaloparatide) / Radius, Teijin
New P3 trial: ACTIVExtend: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis (clinicaltrials.gov) - Aug 2, 2012
P3, N=1200, Recruiting, Sponsor: Radius Health, Inc.
- alendronate / Generic mfg.
Trial initiation date: BOCOMEDEN: Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly (clinicaltrials.gov) - Jul 29, 2012
P=N/A, N=280, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Initiation date: May 2012 --> Sep 2012
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: DIRECT: Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (clinicaltrials.gov) - Jul 16, 2012
P3, N=1262, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Initiation date: May 2012 --> Sep 2012 Active, not recruiting --> Completed
- ||| alendronate / Generic mfg., ibandronate sodium hydrate / Generic mfg.
Trial completion: A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=6054, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Evenity (romosozumab) / Astellas, Amgen, UCB
New P3 trial: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jun 27, 2012
P3, N=4000, Recruiting, Sponsor: Amgen
- odanacatib (MK-0822) / Merck (MSD)
Trial withdrawal: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Merck
Recruiting --> Completed Not yet recruiting --> Withdrawn
- odanacatib (MK-0822) / Merck (MSD)
Enrollment change: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Merck
Not yet recruiting --> Withdrawn N=1378 --> 0
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: Transition From Alendronate to Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 29, 2012
P1, N=60, Completed, Sponsor: Amgen
- |||||| alendronate / Generic mfg.
Enrollment open: BILANZ: Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy (clinicaltrials.gov) - Mar 20, 2012
P3, N=7000, Recruiting, Sponsor: Evangelisches Krankenhaus Lutherhaus gGmbH
N=1378 --> 0 Not yet recruiting --> Recruiting
- odanacatib (MK-0822) / Merck (MSD)
New P3 trial: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) (clinicaltrials.gov) - Mar 11, 2012
P3, N=0, Withdrawn, Sponsor: Merck
- | raloxifene hydrochloride / Generic mfg., alendronate / Generic mfg.
New P4 trial, Monotherapy: Confors: Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis (clinicaltrials.gov) - Feb 15, 2012
P4, N=125, Completed, Sponsor: Medical University of Vienna
- alendronate / Generic mfg.
Enrollment open: Pharmacokinetics of Maxmarvil (clinicaltrials.gov) - Feb 12, 2012
P1, N=20, Recruiting, Sponsor: Yuyu Pharma, Inc.
Not yet recruiting --> Recruiting Available --> Recruiting
- | alendronate / Generic mfg.
New P1 trial: Pharmacokinetics of Maxmarvil (clinicaltrials.gov) - Jan 31, 2012
P1, N=20, Recruiting, Sponsor: Yuyu Pharma, Inc.
- |||||||||| alendronate / Generic mfg.
New P3 trial: BILANZ: Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy (clinicaltrials.gov) - Jan 10, 2012
P3, N=7000, Recruiting, Sponsor: Evangelisches Krankenhaus Lutherhaus gGmbH
- | risedronate / Generic mfg., alendronate / Generic mfg.
Trial completion: Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients (clinicaltrials.gov) - Dec 14, 2011
P3, N=250, Completed, Sponsor: University of Alberta
Available --> Recruiting Active, not recruiting --> Completed
- ||| odanacatib (MK-0822) / Merck (MSD)
Enrollment change: A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042) (clinicaltrials.gov) - Nov 20, 2011
P2a, N=247, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=160 --> 247
- |||| odanacatib (MK-0822) / Merck (MSD)
Trial completion: A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042) (clinicaltrials.gov) - Nov 20, 2011
P2a, N=247, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=160 --> 247 Active, not recruiting --> Completed
- alendronate / Generic mfg.
Trial withdrawal: AlenPostPara: The Effects of Alendronate After Cure of Primary Hyperparathyroidism (clinicaltrials.gov) - Nov 14, 2011
P4, N=0, Withdrawn, Sponsor: Columbia University
Active, not recruiting --> Completed Completed --> Withdrawn
- alendronate / Generic mfg.
Enrollment change: AlenPostPara: The Effects of Alendronate After Cure of Primary Hyperparathyroidism (clinicaltrials.gov) - Nov 14, 2011
P4, N=0, Withdrawn, Sponsor: Columbia University
Completed --> Withdrawn N=40 --> 0
- | alendronate / Generic mfg.
New P2 trial: Testosterone and Alendronate in Hypogonadal Men (clinicaltrials.gov) - Oct 25, 2011
P2, N=100, Recruiting, Sponsor: Massachusetts General Hospital
- alendronate / Generic mfg., pamidronate disodium / Generic mfg.
Trial completion: Bisphosphonate Therapy for Osteogenesis Imperfecta (clinicaltrials.gov) - Sep 25, 2011
P4, N=30, Completed, Sponsor: Indiana University School of Medicine
N=40 --> 0 Recruiting --> Completed
- || risedronate / Generic mfg., alendronate / Generic mfg.
Enrollment change: Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=105, Completed, Sponsor: Warner Chilcott
Recruiting --> Completed N=47 --> 105
- || risedronate / Generic mfg., alendronate / Generic mfg.
Enrollment change: Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=105, Completed, Sponsor: Warner Chilcott
N=47 --> 105 N=52 --> 105
- alendronate / Generic mfg.
Enrollment closed: Cyclic Versus Daily Teriparatide on Bone Mass (clinicaltrials.gov) - Sep 7, 2011
P2, N=140, Active, not recruiting, Sponsor: Helen Hayes Hospital
N=52 --> 105 Recruiting --> Active, not recruiting
- prednisone / Generic mfg., alendronate / Generic mfg.
Trial termination: Glucocorticoids Promote Osteoclast Survival (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=3, Terminated, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Terminated due to recruitment problems
- prednisone / Generic mfg., alendronate / Generic mfg.
Enrollment change: Glucocorticoids Promote Osteoclast Survival (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=3, Terminated, Sponsor: University of Arkansas
Active, not recruiting --> Terminated; Terminated due to recruitment problems N=60 --> 3
- || alendronate / Generic mfg.
New P3 trial: A-15 week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Alendronate plus Vitamin D3 in women with osteoporosis (EUDRACT) - Aug 10, 2011
P3, N=450, Ongoing, Sponsor: Teva Pharmaceutical Industries Ltd.